Literature DB >> 22056820

Lone atrial fibrillation: where are we now?

Tatjana S Potpara1, Gregory Y Lip.   

Abstract

There is a growing pandemic of atrial fibrillation (AF), affecting nearly 2% of the general adult population. Atrial fibrillation is commonly associated with structural heart disease, and AF itself causes a sequence of complex processes of electrical, contractile, and structural remodeling of the atrial myocardium, which facilitate further AF progression. Nonetheless, AF may also affect individuals aged ≤ 65 years who have no evidence of associated cardiopulmonary or other disease, including hypertension; this is otherwise referred to as "lone" AF and is considered to have a generally favorable prognosis. The true prevalence of lone AF is unknown. Growing insights into the diversity of numerous mechanisms involved in the pathogenesis of AF, including acute atrial stretch, structural and electrophysiological alterations, systemic inflammation, oxidative stress, autonomic imbalance, genetic predisposition, and many others, and increasing recognition of novel risk factors for AF, including obesity, metabolic syndrome, subclinical atherosclerosis, sleep apnea, alcohol consumption, and endurance sports, suggest that apparently lone AF might not be so "lone" in many patients, which could have important prognostic and therapeutic implications. In this article, we summarize the current knowledge of epidemiology, etiopathogenesis, and pathophysiology of so-called lone AF and discuss the issues of long-term prognosis and management of patients who have an apparently lone AF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056820     DOI: 10.3810/hp.2011.10.919

Source DB:  PubMed          Journal:  Hosp Pract (1995)        ISSN: 2154-8331


  3 in total

1.  Clinically unrecognized mitral regurgitation is prevalent in lone atrial fibrillation.

Authors:  Sanjiv Sharma; Joel Lardizabal; Mark Monterroso; Neil Bhambi; Rohan Sharma; Rasham Sandhu; Sarabjeet Singh
Journal:  World J Cardiol       Date:  2012-05-26

2.  Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).

Authors:  Eun-Jeong Kim; Xiaoyan Yin; João D Fontes; Jared W Magnani; Steve A Lubitz; David D McManus; Sudha Seshadri; Ramachandran S Vasan; Patrick T Ellinor; Martin G Larson; Emelia J Benjamin; Michiel Rienstra
Journal:  Am Heart J       Date:  2016-04-30       Impact factor: 4.749

3.  Diagnostic Efficacy of Cardiac Scintigraphy with 99mTc-Pyrophosphate for Latent Myocardial Inflammation in Patients with Atrial Fibrillation.

Authors:  Julia Ilyushenkova; Svetlana Sazonova; Konstantin Zavadovsky; Roman Batalov; Yuliya Rogovskaya; Yana Anfinogenova; Yurii Lishmanov
Journal:  Cardiol Res Pract       Date:  2020-03-16       Impact factor: 1.866

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.